Resistin and obesity-associated insulin resistance

被引:407
作者
Steppan, CM [1 ]
Lazar, MA
机构
[1] Univ Penn, Med Ctr, Div Endocrinol Diabet & Metab, Dept Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Med Ctr, Div Endocrinol Diabet & Metab, Dept Genet, Philadelphia, PA 19104 USA
关键词
D O I
10.1016/S1043-2760(01)00522-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Obesity is a major risk factor for insulin resistance and type 2 diabetes mellitus. Adipocytes secrete numerous substances that might contribute to peripheral insulin sensitivity. These include leptin, tumor necrosis factor a, Acrp30/adiponectin/adipoQ and interleukin 6, the potential roles of which are briefly reviewed here. Thiazolidinedione (TZD) antidiabetic drugs regulate gene transcription by binding to peroxisome proliferator activated receptor gamma, a nuclear hormone receptor found at its highest levels in adipocytes. A search for genes that are downregulated by TZDs in mouse adipocytes led to the discovery of an adipose-specific secreted protein called resistin. Resistin circulates in the mouse, with increased levels in obesity, and has effects on glucose homeostasis that oppose those of insulin. Thus, resistin is a potential link between TZDs, obesity and insulin resistance in the mouse. Future studies must address the mechanism of action and biological role of resistin and related family members in mice and humans.
引用
收藏
页码:18 / 23
页数:6
相关论文
共 78 条
[51]   Insulin resistance and Type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle [J].
Nagaev, I ;
Smith, U .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 285 (02) :561-564
[52]  
Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803
[53]   EFFECTS OF THE OBESE GENE-PRODUCT ON BODY-WEIGHT REGULATION IN OB/OB MICE [J].
PELLEYMOUNTER, MA ;
CULLEN, MJ ;
BAKER, MB ;
HECHT, R ;
WINTERS, D ;
BOONE, T ;
COLLINS, F .
SCIENCE, 1995, 269 (5223) :540-543
[54]   Mechanisms by which thiazolidinediones enhance insulin action [J].
Reginato, MJ ;
Lazar, MA .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1999, 10 (01) :9-13
[55]   MULTIPLE LIPOLYSIS DEFECTS IN THE INSULIN-RESISTANCE (METABOLIC) SYNDROME [J].
REYNISDOTTIR, S ;
ELLERFELDT, K ;
WAHRENBERG, H ;
LITHELL, H ;
ARNER, P .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (06) :2590-2599
[56]   Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action [J].
Rossetti, L ;
Massillon, D ;
Barzilai, N ;
Vuguin, P ;
Chen, W ;
Hawkins, M ;
Wu, J ;
Wang, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (44) :27758-27763
[57]   New perspectives into the molecular pathogenesis and treatment of Type 2 diabetes [J].
Saltiel, AR .
CELL, 2001, 104 (04) :517-529
[58]   Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice [J].
Samad, F ;
Loskutoff, DJ .
MOLECULAR MEDICINE, 1996, 2 (05) :568-582
[59]   Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans [J].
Savage, DB ;
Sewter, CP ;
Klenk, ES ;
Segal, DG ;
Vidal-Puig, A ;
Considine, RV ;
O'Rahilly, S .
DIABETES, 2001, 50 (10) :2199-2202
[60]   A NOVEL SERUM-PROTEIN SIMILAR TO C1Q, PRODUCED EXCLUSIVELY IN ADIPOCYTES [J].
SCHERER, PE ;
WILLIAMS, S ;
FOGLIANO, M ;
BALDINI, G ;
LODISH, HF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (45) :26746-26749